Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Lipoprotein(a) explained: the inherited cholesterol risk

    Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose level is about 90% inherited; raised Lp(a) affects about one in five people and is a causal risk factor for heart disease and aortic valve disease.[1][2] US and European guidance now recommends testing it once in adulthood. No targeted Lp(a) drug is approved, and in September 2026 the first big outcome trial of an Lp(a)-lowering drug, pelacarsen, missed its main goal.[3][4][5]

    Editor reviewedStrict sourcingUpdated ExplainerHealth and medicine, GLP-1 and metabolic medicine, Life sciences

    Most cholesterol risk can be changed by diet, exercise or statins. Lp(a) mostly cannot. It is inherited and common.[1] This page explains what it is and what changed in 2026: a new US testing recommendation and a high-profile drug trial failure.

    This page is general information, not medical advice. Talk to a clinician about whether to test and what a result means for you.

    What Lp(a) is

    Lp(a) (say “L-P-little-a”) is a particle in the blood that carries cholesterol. Your level is about 90% set by your genes and barely moves with diet or lifestyle.[1] About one person in five has raised Lp(a).[1] A high level raises the risk of heart attack and stroke, and is linked to calcium build-up in the aortic valve.[2]

    The European Atherosclerosis Society’s 2022 consensus says epidemiologic and genetic studies of hundreds of thousands of people strongly support a causal, continuous association between Lp(a) concentration and cardiovascular outcomes across ethnicities. It adds that elevated Lp(a) is a risk factor even when LDL is very low, and that high Lp(a) is associated with aortic-valve micro- and macrocalcification.[2] Because Lp(a) is about 90% genetically determined, a single measurement is usually informative for life.[1][3]

    Who should be tested

    The 2026 ACC/AHA dyslipidemia guideline made a one-time Lp(a) test for every adult a Class I recommendation. Because lifestyle changes minimally affect Lp(a), repeat testing is generally not needed.[3] The European Atherosclerosis Society has recommended testing at least once in adults since 2022.[4] A standard lipid panel reports LDL, HDL, triglycerides and total cholesterol, so an Lp(a) test usually has to be requested on its own.[6]

    What doctors can do today

    Without an approved Lp(a)-lowering drug, the EAS recommends early, intensive management of overall risk. In practice that means LDL cholesterol in particular. Lipoprotein apheresis, a blood-filtering procedure, is an option for very high Lp(a) with progressive disease.[7] Some LDL drugs also lower Lp(a) somewhat. The oral PCSK9 inhibitor enlicitide lowered Lp(a) more than placebo in its main trial, though that trial was not designed to test Lp(a)-driven outcomes.[8] See pcsk9-inhibitors.

    The 2026 pelacarsen result and what comes next

    On 4 September 2026 Novartis said its Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint. The trial enrolled 8,323 people with raised Lp(a) and established cardiovascular disease, and the endpoint was fewer cardiovascular events than placebo. The drug did lower Lp(a), and full data are due at a medical congress.[5] The EAS had said in 2022 that trials like this were critical to confirm that lowering Lp(a) helps.[7]

    Two more outcome trials are running: Amgen’s OCEAN(a)-Outcomes trial of olpasiran (7,297 participants, estimated primary completion March 2028) and Lilly’s ACCLAIM-Lp(a) trial of lepodisiran (estimated primary completion March 2029).[9] CRISPR Therapeutics is also developing a gene-editing candidate, CTX321, aimed at the LPA gene;[10] see the gene editing tracker. Developments are logged in the cholesterol and fasting tracker.

    Next in the crash course

    More in Health & medicine

    Developing in Health

    Questions readers ask

    What is Lp(a)?

    Lp(a) is a cholesterol-carrying particle. Its level is about 90% genetically determined and largely unaffected by diet or lifestyle, and raised Lp(a) affects about one in five people worldwide.[1]

    Should I get my Lp(a) tested?

    The 2026 ACC/AHA guideline recommends that every adult have Lp(a) measured at least once, and European guidance also recommends a one-time test. Because lifestyle barely changes it, repeat testing is generally not needed. Ask a clinician about testing.[3][4]

    Can diet or exercise lower Lp(a)?

    Not meaningfully. Lp(a) is about 90% inherited and largely unaffected by diet or lifestyle, according to Novartis, and the 2026 guideline says lifestyle changes minimally affect it.[1][3]

    Is there a drug for high Lp(a)?

    No targeted Lp(a) drug was approved as of September 2026. Pelacarsen lowered Lp(a) but failed to reduce cardiovascular events in the Lp(a)HORIZON trial. Olpasiran and lepodisiran outcome trials are due to finish in 2028 and 2029.[1][5][9]

    What do doctors do if Lp(a) is high?

    The European Atherosclerosis Society recommends early, intensive management of other risk factors, especially LDL cholesterol, and lists lipoprotein apheresis as an option for very high Lp(a) with progressive disease.[7]

    Sources

    · 10 claims from 9 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Elevated Lp(a) is an inherited risk factor affecting about one in five people worldwide; Lp(a) levels are about 90% genetically determined and largely unaffected by diet or lifestyle, and no targeted Lp(a) treatment was approved as of September 2026. confirmedas of 2026-10-11

    2. [2]

      The European Atherosclerosis Society's 2022 consensus statement says epidemiologic and genetic studies strongly support a causal, continuous link between Lp(a) concentration and cardiovascular outcomes, that high Lp(a) is a risk factor even at very low LDL levels, and that it is associated with aortic valve calcification. confirmedas of 2026-10-11

    3. [3]

      The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood (a Class I recommendation), noting that lifestyle changes minimally affect Lp(a) so repeat testing is generally not needed. confirmedas of 2026-10-11

    4. [4]

      The European Atherosclerosis Society's 2022 consensus statement recommends testing Lp(a) at least once in adults, and Novartis states that US and European guidelines both recommend once-in-a-lifetime Lp(a) testing for all adults. confirmedas of 2026-10-11

    5. [5]

      On 4 September 2026 Novartis announced that its Phase III Lp(a)HORIZON trial of pelacarsen (8,323 patients with elevated Lp(a) and established cardiovascular disease) did not meet its primary endpoint of reducing cardiovascular events versus placebo, even though Lp(a) levels were lowered; full data are to be presented at a medical congress. Ionis described it as the first pivotal Phase 3 trial to test whether lowering Lp(a) reduces cardiovascular risk. confirmedas of 2026-10-11

    6. [6]

      A standard cholesterol check (lipid panel) measures LDL cholesterol, which can lead to plaque buildup in arteries; HDL cholesterol, high levels of which are linked to lower heart disease and stroke risk; triglycerides, a blood fat used for energy; and total cholesterol. confirmedas of 2026-10-11

      • About Cholesterol · Centers for Disease Control and Prevention · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
      • About Cholesterol · Centers for Disease Control and Prevention · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
    7. [7]

      Without specific Lp(a)-lowering drugs, the EAS consensus recommends early intensive management of other risk factors, lists lipoprotein apheresis as an option for very high Lp(a) with progressive disease, and says trials of Lp(a)-lowering treatments are critical to confirm benefit. confirmedas of 2026-10-11

    8. [8]

      In the CORALreef Lipids trial (2,909 adults with or at risk of atherosclerotic cardiovascular disease), oral enlicitide 20 mg daily lowered LDL cholesterol by 55.8 percentage points more than placebo at week 24, also lowered non-HDL cholesterol, apolipoprotein B and Lp(a), and adverse events did not appear to differ from placebo. confirmedas of 2026-10-11

    9. [9]

      Two other Lp(a)-lowering outcome trials were active but not recruiting as of October 2026, Amgen's OCEAN(a)-Outcomes trial of olpasiran (7,297 participants, estimated primary completion March 2028) and Lilly's lepodisiran trial ACCLAIM-Lp(a) (estimated 17,300 participants, estimated primary completion March 2029). confirmedas of 2026-10-11

    10. [10]

      CRISPR Therapeutics' disclosed in vivo liver-editing portfolio in October 2026 comprises CTX310 (ANGPTL3), CTX340 (angiotensinogen, for refractory hypertension), CTX321 (LPA, for elevated lipoprotein(a)) and CTX460 (SERPINA1, for alpha-1 antitrypsin deficiency), the last using the company's proprietary SyNTase editing technology. confirmedas of 2026-10-08

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.

    Cite this page

    "Lipoprotein(a) explained: the inherited cholesterol risk." ContentLora, updated Oct 11, 2026. https://contentlora.com/explain/lipoprotein-a-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents